Nanologica Ab · OMXSTO:NICA
Nanologica Ab — Q4 2023 Earnings Presentation
29 slides from Nanologica Ab's earnings presentation, Feb 2, 2024
Slide 1: Year-End Report 2023
YEAR-END REPORT 2023 N A N O LO G I C A A B ( PU B L )
Slide 2: Period in Brief
PERIOD IN BRIEF FINANCIAL SUMMARY • Net sales for the fourth quarter amounted to TSEK 75 (674) and for the full year to TSEK 1,443 (1,555) • The operating loss for the quarter amounted to TSEK -35,638 (-13,251) and for the full year to TSEK -69,963 (-50,850). Operating loss was affected by write-dow
Slide 3: Comment from the CEO
COMMENT FROM THE CEO During the last quarter of the year, Nanologica took clear steps forward. The production problems we have wrestled with during the year have now been handled and several deliveries to customers have been made. After rigorous testing of our silica-based purification media NLAB Sa
Slide 4: CEO comment continued: NLAB Siv and financial position
To this end, we have for a long time worked with a customer to develop a non-silica-based purification media, NLAB Siv . Manufacturing takes place at a partner and in November we received the first order for NLAB Siv at a value of MSEK 3.6. The customer will test the product in their production, aft
Slide 5: This is Nanologica
THIS IS NANOLOGICA Better and cheaper medicine to a larger number of patients Nanologica is a Swedish life science tools company that provides consumables to pharmaceutical manufacturers. With a foundation in materials science and nanotechnology, the company has developed an expertise in chromatogra
Slide 6: Five Reasons to Invest in Nanologica
FIVE REASONS TO INVEST IN NANOLOGICA By developing chromatography products that enable pharmaceutical manufacturers to streamline production and lower their production costs, Nanologica not only strives to create value for its shareholders, but also to contribute to more patients having access to ad
Slide 7: Business Area Chromatography
BUSINESS AREA CHROMATOGRAPHY In October, silica-based purification media was During the fourth quarter, Nanologica delivered to an insulin manufacturer in Asia participated in TIDES Europe in Amsterdam, and against an order placed in 2022. The delivery of in Purify – Chromatography Purification NLAB
Slide 8: Business Area Drug Development; Operating Income and Result
BUSINESS AREA DRUG of which development costs of TSEK -4,738 related to the drug development business area, DEVELOPMENT and -9,785 related to prepaid production costs The business area has since May 2023 been for silica. Operating loss also includes down-prioritized. At the end of the year, the depr
Slide 9: Investments, Liquidity and Financial Position
parent company had tax loss deduction commitment. The company has no right to a amounting to TSEK 341,749. The tax loss refund in the event of decreased demand for any deductions may be activated when the reason. At the end of the year, prepaid requirements for activation of the deferred tax product
Slide 10: Fluctuations in Revenue Generation; Preferential Rights Issue
both the group’s and the parent company's FLUCTUATIONS IN REVENUE equity are expected to be restored. GENERATION The equity/assets ratio as of 31 December 2023 Chromatography generates revenue through the was -2 percent, compared with 47 percent at the sales of products for preparative and analytica
Slide 11: Financial Calendar, Nomination Committee, Annual General Meeting
Shareholders 31 December 2023 FINANCIAL CALENDAR Annual Report 2023 22 March 2024 Registered owners per 31 December, Shares, Share 2023 number % Interim Report Q1 2024 26 April 2024 Interim Report Q2 2024 5 July 2024 Flerie Invest AB 14,901,635 41.2 Interim Report Q3 2024 25 October 2024 Swedbank Ro
Slide 12: Future Prospects, Risks and Uncertainties, External Factors
FUTURE PROSPECTS characterized 2023. Nanologica does not conduct This report contains forward-looking statements. any business linked to Ukraine or Russia and the Actual outcomes may differ from these war has not had any direct impact on the statements. Internal and external factors can company. How
Slide 13: Auditors Review and Assurance
AUDITORS REVIEW 2 February 2024 This year-end report has not been subject to review by the company’s auditors. Gisela Sitbon Mattias Bengtsson Chairman of the board Board member ASSURANCE The board of directors and the CEO provide their assurance that this interim report provides a fair and true ove
Slide 14: Financial Reports and Notes
(SNA GICA FINANCIAL REPORTS AND NOTES
Slide 15: Consolidated Income Statement
CONSOLIDATED INCOME STATEMENT 2023 2022 2023 2022 Amounts in TSEK Oct - Dec Oct - Dec Jan - Dec Jan - Dec Net sales 75 674 1 443 1 555 Change in inventories, finished goods 1 457 -197 2 080 -1 276 Capitalized work for own use 866 1 527 3 229 4 272 Other operating income 228 71 494 265 Operating expe
Slide 16: Consolidated Balance Sheet
CONSOLIDATED BALANCE SHEET 2023 2022 Amounts in TSEK Dec 31 Dec 31 ASSETS Fixed assets Intangible fixed assets Capitalized expenditure for research and development and similar 21 809 14 724 Concessions, patents, licenses, trademarks and similar rights 1 332 1 407 Tangible fixed assets 3 749 3 181 Ri
Slide 17: Consolidated Changes in Equity and Cash Flow Statement
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY 2023 2022 2023 2022 Amounts in TSEK Oct - Dec Oct - Dec Jan - Dec Jan - Dec Total equity at the beginning of the period 34 840 9 503 73 158 51 596 Profit/loss for the year -36 839 -14 855 -75 157 -55 231 Other comprehensive income 0 0 0 0 Total comprehensi
Slide 18: Notes
NOTES NOTE 1 GENERAL INFORMATION This report covers the Swedish parent company Nanologica AB (publ), corporate registration number 556664-5023, and its subsidiaries. The parent company is a limited liability company with its registered office in Stockholm, Sweden. The address of the main office is F
Slide 19: Operating Segments
operating segments is consistent with the internal reports that the group's highest executive decision- makers use to monitor operations and allocate resources among operating segments. The CEO is the group's highest executive decision-maker. In Nanologica, it is therefore the reports that the CEO r
Slide 20: Segment Results 2022
2022 Jan - Dec Amounts in TSEK Chroma DD Corp Function Total Net sales 1 555 0 0 1 555 Raw materials, consumables and change in inventories -2 528 -64 0 -2 592 Gross profit -973 -64 0 -1 037 Other operating items -22 684 -11 003 -16 127 -49 814 Operating profit/loss -23 656 -11 067 -16 127 -50 850 N
Slide 21: Financial Assets Valued at Fair Value
NOTE 6 FINANCIAL ASSETS VALUED AT FAIR VALUE Fair value valuation IFRS 13 Fair value valuation contains a valuation hierarchy regarding input to the valuations. This valuation hierarchy is divided into three levels, consisting of: • Level 1 - Quoted prices on active markets for identical assets and
Slide 22: Related Party Transactions and Loans
More information on transactions with related parties can be found in Nanologica's annual report 2022, note 35. Information regarding loans Loans from Flerie Invest AB amounted to MSEK 67 on the balance sheet day and were raised on market terms. Loan 1 totaling MSEK 17 was raised during autumn 2019
Slide 23: Alternative Performance Measure Definitions
Alternative performance measure definitions Operating profit/loss (EBIT) Profit/loss before net financial items and taxes. (Earnings Before Interest and Taxes). Operating margin, %* Operating profit/loss in relation to net sales. In cases where the margin is negative, the margin is only reported as
Slide 24: Group Quarterly Data
GROUP QUARTERLY DATA Amounts in TSEK unless otherwise stated 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 Statement of comprehensive income Net sales 75 342 672 355 674 401 210 270 Total operating expenses -38 265 -10 467 -15 676 -12 801 -15 326 -11 421 -13 796 -15 122 Operating p
Slide 25: Income Statement for the Parent Company
INCOME STATEMENT FOR THE PARENT COMPANY 2023 2022 2023 2022 Amounts in TSEK Oct - Dec Oct - Dec Jan - Dec Jan - Dec Net sales 75 674 1 443 1 555 Change in inventories, finished goods 1 457 -197 2 080 -1 276 Capitalized work for own use 866 1 527 3 229 4 272 Other operating income 228 71 494 265 Oper
Slide 26: Balance Sheet for the Parent Company
BALANCE SHEET FOR THE PARENT COMPANY 2023 2022 Amounts in TSEK 31 Dec Dec 31 ASSETS Fixed assets Intangible assets Capitalized expenditure for research and development and similar 27 391 24 479 Concessions, patents, licenses, trademarks and similar rights 1 332 1 407 Total intangible assets 28 723 2
Slide 27: Balance Sheet for the Parent Company
BALANCE SHEET FOR THE PARENT COMPANY 2023 2022 Amounts in TSEK 31 Dec Dec 31 EQUITY AND LIABILITIES Equity Share capital 14 821 14 821 Fund for development expenditure 748 6 571 Total restricted equity 15 569 21 392 Non-restricted equity Share premium reserve 308 295 308 195 Profit/loss brought forw
Slide 28: Parent Company Changes in Equity and Cash Flow
STATEMENT OF CHANGES IN EQUITY FOR THE PARENT COMPANY 2023 2022 2023 2022 Amounts in TSEK Oct - Dec Oct - Dec Jan - Dec Jan - Dec Total equity at the beginning of the period 29 990 5 328 68 840 47 834 Rights issue 0 79 699 0 79 803 Premiums for issued / repurchased warrants 100 0 100 0 Issue costs 0
Slide 29: Nanologica AB (publ) contact details
Nanologica AB (publ) Forskargatan 20 G SE-151 36 Södertälje Sweden Ph: +46-8-410 749 49 www.nanologica.com